MOSCETTI, ALESSANDRO
 Distribuzione geografica
Continente #
NA - Nord America 628
EU - Europa 247
AS - Asia 123
SA - Sud America 7
Totale 1.005
Nazione #
US - Stati Uniti d'America 610
IT - Italia 66
IN - India 50
UA - Ucraina 50
SE - Svezia 46
SG - Singapore 37
CN - Cina 36
FI - Finlandia 26
BG - Bulgaria 19
DE - Germania 18
CA - Canada 16
GB - Regno Unito 10
IE - Irlanda 5
RO - Romania 4
AR - Argentina 3
BO - Bolivia 2
BR - Brasile 2
GR - Grecia 2
MX - Messico 2
CH - Svizzera 1
Totale 1.005
Città #
Chandler 97
Fairfield 63
Ashburn 35
Seattle 34
Dearborn 32
Woodbridge 30
Wilmington 29
Princeton 25
Plano 24
Rome 23
Beijing 22
Singapore 22
Cambridge 20
Sofia 19
Houston 17
Jacksonville 16
Boston 14
Des Moines 11
Bremen 10
Ann Arbor 9
Southend 9
Andover 7
Millbury 7
Cagliari 6
Toronto 6
Dublin 5
Ospedaletti 5
Boardman 4
Formello 4
Norwalk 4
San Diego 4
San Paolo di Civitate 4
Federal 3
Hefei 3
Kunming 3
Lawrence 3
Pune 3
Americana 2
Bühl 2
Caserta 2
Falls Church 2
Helsinki 2
La Paz 2
Mexico City 2
Quzhou 2
San Mateo 2
Santa Clara 2
Torino 2
Bern 1
Buffalo 1
Canicattì 1
Capodrise 1
Changsha 1
Florence 1
Foggia 1
Fremont 1
Fuzhou 1
Guangzhou 1
Jinan 1
Langfang 1
Laurel 1
Mannheim 1
Montréal 1
Nanjing 1
Phoenix 1
Pisa 1
Pomezia 1
Portland 1
Reggio Emilia 1
San Francisco 1
Willowdale 1
Totale 677
Nome #
Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse 84
PSEUDOXANTHOMA ELASTICUM AND LIGHT-CHAIN AMYLOIDOSIS 77
Valuation of MCP-1 and VEGF Chemokines In Serum of Patients with AL Amyloidosis 66
IL-4 and IL-1 Serum Levels In Systemic and Localized Amyloidosis 57
Heart Function In Systemic and Localized AL Amyloidosis: Role of NT-ProBNP and MPC-1 54
MR-proANP and MCP-1 as effective biomarkers of cardiac and microvascular inflammatory impairment in systemic AL amyloidosis patients treated with MEL-DEX association. 53
Studio multicentrico sulle varianti dell'antigene D nella popolazione italiana:dati preliminari del progetto Arcobaleno 48
NT-ProBNP and VEGF Serum Evaluation In AL Amyloidosis 47
A CASE OF KLEBSIELLA PNEUMONIAE LIVER ABSCESS IN A PATIENT AFFECTED BY THALASSEMIA INTERMEDIA 45
CHEMOTHERAPY AND ANTIVIRAL THERAPY IN HHV8+, HIV NEGATIVE ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE: A CASE REPORT 43
CYSTATIN C, B2-MICROGLOBULIN AND ALKALINE PHOSPHATASE SERUM LEVELS IN AL AMYLOIDOSIS 41
ASSOCIATION OF BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA 41
USE OF TEMOZOLOMIDE IN THE TREATMENT OF ADVANCED CENTRAL NERVOUS SYSTEM (CNS) NON HODGKIN LYMPHOMA 36
Correlation between serum levels of free light chain and circulating cytokines in a patient with AL cardiac amyloidosis 36
MCP-1 and VGEF markers in the evaluation of systemic AL amyloidosis response to Upfront Melphalan-Dexamethasone Association. 35
DIFFERENCE IN SERUM CYTOKINES PATTERN BETWEEN SYSTEMIC AND LOCALIZED AL AMYLOIDOSIS 34
Clinical role of IL-6 and IL-1B in IgG and IgA multiple myeloma 34
Studio muticentrico sulle varianti dell'antigene D nella popolazione italiana: dati preliminati del "Progetto Arcobaleno" 33
Renal function improvement evaluated by cystatin-C serum levels in patients with systemic AL amyloidosis treated with MEL-DEX association 32
MULTIPLE MYELOMA AND MGUS: A SERUM EVALUATION OF PCT, MR-PROAMD AND MR PROANP 29
CORRELAZIONE FRA QUADRO MORFOFUNZIONALE CARDIACO VALUTATO MEDIANTE RISONANZA MAGNETICA ED ECOCARDIOGRAFIA E QUADRO BIOUMORALE IN PAZIENTI AFFETTI DA AMILOIDOSI AL 28
MR-PROADM as marker of vascular damage reversibility in AL amyloidosis patients. 25
MR-ProANP: A POSSIBLE ADDITIONAL CARDIAC MARKER IN AL AMYLOIDOSIS 24
TH1 and TH2 cells in multiple myeloma 23
Totale 1.025
Categoria #
all - tutte 2.647
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.647


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020196 0 3 3 14 19 45 31 26 19 20 11 5
2020/202154 11 6 2 2 0 6 1 9 3 9 4 1
2021/2022191 4 9 14 8 34 3 0 18 13 19 21 48
2022/2023256 49 26 13 42 35 29 4 15 37 1 4 1
2023/2024141 9 24 1 3 11 37 1 22 0 9 11 13
2024/202522 10 12 0 0 0 0 0 0 0 0 0 0
Totale 1.025